Loading...
XLON
VLG
Market cap110mUSD
Oct 09, Last price  
69.00GBP
1D
0.00%
1Q
3.76%
IPO
-32.59%
Name

Venture Life Group PLC

Chart & performance

D1W1MN
XLON:VLG chart
P/E
13.62
P/S
2.37
EPS
0.05
Div yield, %
—
Shrs. gr., 5y
8.43%
Rev. gr., 5y
3.18%
Revenues
35m
+32.24%
101,000395,000292,000486,0007,189,0009,077,00014,280,00016,052,00018,770,00020,206,00030,076,00032,762,00043,980,00051,410,00026,593,00035,167,000
Net income
6m
P
-209,000-417,000-788,000-1,081,000-1,570,000-1,761,000-1,369,000-367,000236,000904,0002,368,0002,402,000520,000921,000-314,0006,125,000
CFO
-264k
L
-250,000-479,000-516,000-1,035,000-2,224,000-1,109,000-457,000-84,000238,0002,441,0002,706,000601,0005,566,0008,220,0008,351,000-264,000
Dividend
May 24, 20180.039945 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in Bracknell, UK, in 2005, Venture Life Group plc is an international developer and marketer of diverse health and personal care items. The company's portfolio spans oral care products, dietary supplements, medical devices, dermo-cosmetics, and topical applications, serving a global market across the United Kingdom, various European countries (including the Netherlands, Germany, Italy, and Switzerland), and China. Operating through its distinct Venture Life Brands and Customer Brands divisions, the company offers a comprehensive array of solutions. These include advanced neurology-focused nutritional supplements such as NeuroAge, NeuroAge Sleep, and NeuroAge NRG, designed to enhance alertness, cognitive abilities, and mental acuity. For hair health, Original Bioscalin addresses hair loss, thinning, and baldness. The Myco Clear range provides antifungal nail solutions, comprising a Fungal Nail Solution for treatment and prevention, and a Fungal Nail Cleanser for foot and hand hygiene. In the realm of oral care, UltraDEX is formulated to combat bad breath, while Dently Dual Action is a mouthwash engineered to effectively remove plaque and bacteria. For anal discomfort, Procto-eze plus offers relief for conditions like haemorrhoids and general irritation. Venture Life also features a dedicated women's healthcare line under the vonalei brand, which includes a refreshing gel for bacterial vaginosis, a vaginal cream for atrophy, a soothing cream-gel for candidiasis (thrush), and an intimate cleansing foam. Its dermo-cosmetic selections encompass the Rosa calma brand's Cleansing Foam, Cleansing Cream, and Serum, alongside the Lubatti Classic and Lubatti Anti-age skincare collections. These skincare lines are meticulously crafted to hydrate, nourish, and recondition the skin, helping to minimize the appearance of lines and wrinkles. The company distributes its extensive product offerings through a broad network that includes international partners, pharmacies, and major grocery retailers.

Key people

Independent Non-Executive Chairman of the Board · since 2025
Daniel Wells
Chief Financial Officer, Executive Director · since 2022
Peter Jackson
Chief Digital and Technology Officer · since 2025
Gianluca Braguti
Executive Director, Chief Manufacturing Officer · since 2014
Jerry Randall
Chief Executive Officer, Executive Director · since 2022
Carl Dempsey
Independent Non-Executive Director · since 2023
IPO date
Mar 28, 2014
Employees
153
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
VENTURE HOUSE
ARLINGTON SQUARE
DOWNSHIRE WAY
BRACKNELL, BRC RG12 1WA
GB
Previous name
VLL HEALTHCARE PLC

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT